



#### Table of contents


- 03. Executive Summary
- 05. Introduction & Methodology
- 08. Industry Sub Sector
- 28. Predictive Talent Market Dynamics









# EVOLUTION SEARCH PARTNERS


















### Introduction & Methodology



+40K Operations, Commercial & Executive profiles Junior/Mid/Senior



5 Year Historic Data x5 node supply chain analysis Supply Trend Analysis CMO, CGT, CRO & Pharma sector



#### Mathematical Modelling

Mathematical modelling of Biomanufacturing talent dynamics'; Monte Carlo; Lotka-Volterra model and K-gamma distribution



Hiring Data: 'metadata analysis using data gathered from website change detection, data mining and public data monitoring







## Insight Report

Research

**Partners** 

To measure, model and predict 'supply versus demand' of Biomanufacturing talent across the global CMO, CGT and Pharma sectors.

Evolution Search Partners; University of Dundee; University College London (UCL)

To provide analytical strategic intelligence to industry leadership to allow future facing workforce planning, aligned to support capital expansion project decisions, recognising the value of human assets in the economic success of the firm.

The outcome data aims to allow specific planning, where required, on creative talent acquisition, specific to segments of biomanufacturing workflows



Aim

Purpose

There is evidence that the bioprocessing sector is experiencing operational and staffing problems directly related to an increase in activity and demand. All sectors are experiencing an increase in R&D, manufacturing & production, with a shifting of resources towards responding to the pandemic Most bioprocessing-related industrial activities are considered 'essential' and continue largely unaffected in terms of operations and output, while many are planning to ramp-up R&D and manufacturing. While there are many near-term changes in onsite staff management, broader business plans are generally not affected in the near-term.

Specific to Biomanufacturing talent, CMO and Pharma companies can no longer wait to develop talent strategies. They already have job openings they cannot fill, and the gap is widening as megatrends disrupt and transform biomanufacturing. Adopting talent management programs and processes will help manufacturers attract and retain workers with the desired skill sets. This is a challenge that requires flexibility and insight. And the stakes are high. Manufacturers with an engaged and skilled workforce will be more likely to enjoy a successful and sustainable future.












# **Industry Sub-Sector**


10 By Job Number – MTD /QTD/ YTD (Normalised)	21 Assessment of Hiring Frequency by Job	о Туре
14 Average Total Job Number - MTD /QTD/ YTD / 2-YTD	26   Market Drivers	
18 Data Summary – Monthly Hiring Insight	28 Predictive Talent Market Dynamics	
























Caribou Biosci CRISPR Ther. MeiraGTx



Arcturus Biocytogen CureVac








Legend Biotech Allogene Ther. Shape Ther.



Arcturus Biocytogen CureVac








Shape Ther.
Editas Medicine
Kura Oncology



Arcturus
Biocytogen
Abeona Ther.







Verve Ther. Instil Bio Sangamo Ther.




Arcturus
Biocytogen
Abeona Ther.






QTD, YTD, 2-YTD
CGT
AVG. TOTAL NUMBER HIRED





Top 10: QTD, YTD, 2-YTD CGT AVG. TOTAL NUMBER HIRED






















#### **Breakdown of Roles Postings**



**YTD** 

(Increasing)

Commercial:

-

**Operations:** 

RegenxBio BlueBird Bio

R&D:

Caribou Biosci. Allogene Ther. MTD

(Increasing)

Commercial:

-

**Operations:** 

BlueBird Bio Intellia Ther.


R&D:


Intellia Ther. Allogene Ther.

















# **DECREASING**













Regenxbio opens state-of-the-art gene therapy manufacturing facility: \$65 million invested in new facility, enabling end-to-end control of gene therapy manufacturing in Montgomery County, Maryland



This has been a year [2022] marked by progress across our pipeline. In the third quarter, we continued to advance our clinical trials and preclinical activities

Pfizer and Sangamo Therapeutics announce phase 3 trial of investigational gene therapy for hemophilia a has re-opened recruitment



Expect cash runway into 2025, enabling multiple data readouts across platforms for lead programs, driven by significant cash savings from manufacturing facility move to Bothell, Washington as well as research prioritization






### **Predictive Talent Market Dynamics**

#### Various models presented below exemplify the 'Supply versus Demand' market growth assumptions:





USA Biomanufacturing Supply versus Demand modelling. Various market growth options. Talent Supply presented at 10% growth (median over 12 years); Talent Demand growth projected at 10% (left) and 20% (right) respectively. Intersecting lines illustrate where talent demand and supply are in equilibrium (Evolution, 2022). Supply refers to number of graduates and post-graduates entering Biomanufacturing industry; demand specific to Biomanufacturing job vacancies.



